The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients

Journal of Clinical Pharmacology

Volumn 43, Issue 6, 2003, Pages 555-564

  Yates, Charles R ^a   Zhang, Wenhui ^a   Song, Pengfei ^a   Li, Shen ^a   Gaber, A Osama ^a   Kotb, Malak ^a   Honaker, Marsha R ^a   Alloway, Rita R ^b   Meibohm, Bernd ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Cyclosporine; Cytochrome P 450 3A5; P glycoprotein; Pharmacogenetics; Pharmacokinetics; Single nucleotide polymorphism; Transplantation

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A5; GLYCOPROTEIN P;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN EXPERIMENT; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MALE; MATHEMATICAL MODEL; MDR1 GENE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE;

EID: 0037906108     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003253617     Document Type: Article

References (38)

1. Katznelson S, Gjertson DW, Cecka JM: The effect of race and ethnicity on kidney allograft outcome. Clin Transpl 1995;379-394.
2. Kahan BD, Welsh M, Schoenberg L, Rutzky LP, Katz SM, Urbauer DL, et al: Variable oral absorption of cyclosporine: a biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996;62(5):599-606.
3. Ward FE, MacQueen JM: Immunogenetic factors that may contribute to ethnic differences in renal allograft survival. Clin Transpl 1996;10(6, Pt. 2):620-624.
4. Chertow GM, Milford EL: Poorer graft survival in African-American transplant recipients cannot be explained by HLA mismatching. Adv Ren Replace Ther 1997;4(1):40-45.
5. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al: Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62(3):248-260.
6. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27(4):383-391.
7. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96(4):1698-1705.
8. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70(2):189-199.
9. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, et al: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002;12(6):437-450.
10. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002;71(4):297-303.
11. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001;47(6):1048- 1052.
12. Min DI, Lee M, Ku YM, Flanigan M: Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther 2000;68(5):478-486.
13. Okimoto R, Dodgson JB: Improved PCR amplification of multiple specific alleles (PAMSA) using internally mismatched primers. Biotechniques 1996;21(1):20-22, 24, 26.
14. Sommer SS, Groszbach AR, Bottema CD: PCR amplification of specific alleles (PASA) is a general method for rapidly detecting known single-base changes. Biotechniques 1992;12(1):82-87.
15. Bottema CD, Sarkar G, Cassady JD, Ii S, Dutton CM, Sommer SS: Polymerase chain reaction amplification of specific alleles: a general method of detection of mutations, polymorphisms, and haplotypes. Methods Enzymol 1993;218:388-402.
16. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al: Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS). Nucleic Acids Res 1989;17(7):2503-2516.
17. Song P, Li S, Meibohm B, Gaber AO, Honaker MR, Kotb M, et al: Detection of MDR1 single nucleotide polymorphisms (SNPs) C3435T and G2677T using real-time PCR. AAPS PharmSci 2002;4(4): article 29.
18. Boeckmann AJ, Beal SL, Sheiner LB: NONMEM Users Guide: Parts I-VIII. San Francisco: NONMEM Project Group, UCSF, 1998.
19. Karlsson MO, Sheiner LB: The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993;21(6):735-750.
20. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359(9300):30-36.
21. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, et al: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002;72(2):209-219.
22. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001;18(10):1400-1404.
23. Keown P, Niese D: Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Kidney Int 1998;54(3):938-944.
24. Barone G, Chang CT, Choc MG Jr, Klein JB, Marsh CL, Meligeni JA, et al: The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group. Transplantation 1996;61(6):875-880.
25. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, et al: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002;62(1):162-172.
26. Kaplan B, Lown K, Craig R, Abecassis M, Kaufman D, Leventhal J, et al: Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation 1999;67(2):333-335.
27. Hebert MF: Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997;27(2-3):201-214.
28. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, et al: Interindividual variability and tissue-specificity in the expression of cytochrome p450 3A mRNA. Drug Metab Dispos 2002;30(10):1108-1114.
29. Moyer TP, Post GR, Sterioff S, Anderson CF: Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood. Mayo Clin Proc 1988;63(3):241-247.
30. Rogerson ME, Marsden JT, Reid KE, Bewick M, Holt DW: Cyclosporine blood concentrations in the management of renal transplant recipients. Transplantation 1986;41(2):276-278.
31. Levy G, Thervet E, Lake J, Uchida K: Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 2002;73(9, Suppl.):S12-S18.
32. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, et al: Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001;358(9279):383-384.
33. Bai S, Liu J, Lu SK, Brunner LJ: In vivo induction of hepatic P-glycoprotein by cyclosporine in the rat. Res Commun Mol Pathol Pharmacol 2001;109(1-2):103-114.
34. Hauser IA, Koziolek M, Hopfer U, Thevenod F: Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells. Kidney Int 1998;54(4):1139-1149.
35. Jette L, Beaulieu E, Leclerc JM, Beliveau R: Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 1996;270(5, Pt. 2):F756-F765.
36. Hitzl M, Drescher S, van der KH, Schaffeler E, Fischer J, Schwab M, et al: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001;11(4):293-298.
37. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002;74(11):1486-1489.
38. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, et al: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003;3(4):477-483.